Neurosense Therapeutics Ltd. NRSN 深 沪
等待开盘 11-25 09:30:00 美东时间
1.06
-0.040
-3.64%
华盛通- 最 高1.24
- 今 开1.12
- 成交量 124.91万股
- 最 低 0.98
- 昨 收 1.10
- 总市值 3132.41万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 4.23%
- 52周最低 0.81
- 委 比 -84.60%
- 总股本 2955.10万
- 历史最高 8.18
- 量 比 1.81
- 振 幅 23.64%
- 历史最低 0.40
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
今天 10:27
FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S. Food and
11-24 22:59
Neurosense Therapeutics Announces Phase 2b PARADIGM Study Results For PrimeC Showing Statistically Significant Reductions In Multiple Micrornas Linked To Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new positive findings
10-06 21:07
NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an announcement. On Septemb...
09-11 02:59
NeuroSense Reports Phase 2 RoAD Trial Results, Says PrimeC Boosts Brain Connectivity In Alzheimer's, Shows Favorable Safety Profile
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profileCAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics
09-11 02:32
NeuroSense Therapeutics announces $500,000 private placement
NeuroSense Therapeutics (NASDAQ:NRSN) announced on Thursday it has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares. Under the terms of t...
09-04 21:16
NeuroSense Announces $500,000 Private Placement Of 333,334 Shares At $1.50/Share
Financing at 40% premium to market price provides near-term bridge to anticipated milestonesCAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical
09-04 20:50
NeuroSense Reports Statistically Significant 18-Month Phase 2b Data Showing PrimeC Slows ALS Progression With Early Treatment Advantage
NeuroSense Therapeutics Ltd. today announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS. ●Statistically significant effect at 18 months (p=0.03) demonstrated by NfL-adjusted
09-02 20:42
NeuroSense Reports Long-Term Safety of PrimeC in ALS Study
The latest update is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). As of A...
08-20 21:57
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
08-15 19:15
